Clinical Trials Logo

Clinical Trial Summary

The magnitude of seasonal RSV epidemics brings each year new logistical challenges for the hospitalization of young infants with bronchiolitis that overwhelm hospital capacities and lead to specific winter plans with deprogramming and mobilization of human and logistical resources. The Covid-19 pandemic has changed the way winter epidemics are presented. For example, the seasonal RSV epidemic was shifted by several months in Lyon, with an impression of a lower incidence of hospitalized cases, with a population of older children and with fewer signs of clinical severity. This is largely attributable to the widespread use of barrier gestures and social distancing measures, known as "non-pharmacological interventions" or NPI. Given the magnitude of the reduction of the RSV epidemic, it is legitimate to analyze the benefits of NPIs to draw lessons for maintaining preventive measures around RSV-vulnerable populations; moreover, new preventive pharmacological interventions are soon to be marketed, whether they are particularly refined and long half-life anti-RSV monoclonal antibodies, RSV vaccines for mothers or for newborns and infants. In this perspective, it is crucial to properly define the populations at risk of severe disease to establish a legitimate hierarchy in the implementation of different preventive strategies. The study of the RSV epidemic is a high potential model because of the convergence of epidemiological, virological, and pharmacological knowledge. However, the study of the impact of the pandemic on the epidemiology of rhinovirus also seems promising because, for reasons unknown to date, it seems that the pandemic did not have the same reducing impact on the rhinovirus epidemic; in the latter case, the interest is to confirm the resistance of this virus and to look for more fundamental explanations, for example, on viral interactions. On a previous study (see NTC 04944160), 519 infants were recruited in the Pre-Covid-19 season population, and 277 infants were recruited in the first Per-Covid-19 season population.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05348655
Study type Observational
Source Hospices Civils de Lyon
Contact Dominique PLOIN, PhD
Phone 04 27 85 56 42
Email dominique.ploin@chu-lyon.fr
Status Not yet recruiting
Phase
Start date June 2022
Completion date July 2025

See also
  Status Clinical Trial Phase
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Completed NCT01158560 - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Phase 3
Completed NCT03605862 - Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection Phase 3
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Not yet recruiting NCT05348707 - Impact of Covid-19 on Rhinovirus Epidemic
Not yet recruiting NCT05348616 - Impact of the Covid-19 on RSV
Recruiting NCT04489381 - Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection Phase 3
Completed NCT04670627 - Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics
Suspended NCT03508479 - Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection Phase 1
Completed NCT02438293 - 'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
Completed NCT05016687 - First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers. Phase 1
Completed NCT02660489 - Effect of OC459 on the Response to Rhinovirus Challenge in Asthma Phase 2
Completed NCT02522832 - Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge N/A
Completed NCT01302418 - Collection and Testing of Respiratory Samples N/A
Completed NCT01249625 - The Respiratory Protection Effectiveness Clinical Trial N/A
Completed NCT01175226 - A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection Phase 2
Completed NCT00394914 - Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295) Phase 2
Withdrawn NCT03024177 - A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection Phase 2